Chiron/Ortho, International Murex settle HCV test patent disputes.
This article was originally published in The Gray Sheet
Executive Summary
CHIRON/ORTHO, INTERNATIONAL MUREX SETTLE HCV PATENT LITIGATION via a worldwide agreement signed Aug. 28. The deal gives Murex a license to sell its hepatitis C virus screening tests in "selected countries excluding North America, European Economic Community members and Japan," and rights to sell its HCV serotyping test worldwide. Chiron/Ortho gets rights to Murex' SAM sample addition monitor technology and an option to market Murex' serotyping test in conjunction with Murex.